Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
CancerVax has agreed to merge with German biopharmaceutical company Micromet. Shareholders of Micromet will own roughly 67.5% of the combined entity, which will be renamed Micromet Inc. CancerVax has struggled to recover after discontinuing development of its lead product, the cancer vaccine Canvaxin, last October. The merger will refuel CancerVax's pipeline by adding Micromet's human monoclonal antibody in Phase II trials to treat prostate and breast cancers and several early-phase antibody-based drugs.
This article has been sent to the following recipient: